<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446797</url>
  </required_header>
  <id_info>
    <org_study_id>A3191332</org_study_id>
    <nct_id>NCT00446797</nct_id>
  </id_info>
  <brief_title>Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain</brief_title>
  <official_title>An Open Label Randomized Multicenter Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy of celecoxib loading dose of 400mg followed by 200 mg twice a day
      (BID) versus oral non-selective NSAIDs in acute pain due to ankle sprain.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline at Day 3 in Pain Visual Analog Scale (VAS) - Per Protocol Population</measure>
    <time_frame>Baseline and day 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pain Visual Analog Scale (VAS) - Modified Intent to Treat Population</measure>
    <time_frame>Baseline and days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Responding (Improving) - MITT Population</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Global Assessment of Ankle Injury</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment of Ankle Injury</measure>
    <time_frame>Days 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief - MITT Population</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Normal Function / Activity</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 1</measure>
    <time_frame>Days 1, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 2</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 3</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 4</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Index</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5A</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5B</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5C</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5D</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5E</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5F</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Question 5G</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Interference Index</measure>
    <time_frame>Days 2, 3 and 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Ankle Sprain</condition>
  <arm_group>
    <arm_group_label>Non-Selective NSAIDS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nsNSAIDs used in real-life standard practice for treatment of pain due to ankle sprain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-selective NSAIDS</intervention_name>
    <description>Non-selective NSAIDs administered at usual (standard) doses.</description>
    <arm_group_label>Non-Selective NSAIDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.</description>
    <arm_group_label>Celecoxib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with first acute ankle sprain episode in the last six months classified as
             grade I or II, confirmed by X-rays, according to the following definitions:

          -  Grade I: When the ligament is stretched but not torn and the anterior talofibular
             ligament is usually involved. The anterior draw test is negative.

          -  Grade II: Moderate sprains which usually result in partial tears af the ligaments,
             primarily the anterior talofibular and possibly the calcaneofibular ligament.
             Ligamentous laxity may be present and there is moderate swelling.

        Exclusion Criteria:

          -  Patients who have a similar injury of the same joint within the last six months; or

          -  clinical evidence of complete rupture of ankle ligaments (third degree sprain), or

          -  requirements for bed rest, hospitalization, surgical intervention for the ankle
             injury; or

          -  evidence of fractures; or non-removable full cast of any tipe; or

          -  presence of bilateral occurrence of ankle injury or ipsilateral ankle and knee injury.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74075-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20221-161</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>01221-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>02720-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio Guadalupe</city>
        <state>Guadalupe, San Jose</state>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Quito</city>
        <state>Pichincha</state>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amman</city>
        <zip>11181 Jordan</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amman</city>
        <zip>11193 Jordan</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Amman</city>
        <zip>22110 Jordan</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>10700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toluca</city>
        <state>Estado de México</state>
        <zip>50180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>México DF</city>
        <state>México</state>
        <zip>03020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Nicolas de los Garza</city>
        <state>Nuevo León</state>
        <zip>66451</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lima</city>
        <zip>L27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Costa Rica</country>
    <country>Ecuador</country>
    <country>Egypt</country>
    <country>Jordan</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Peru</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191332&amp;StudyName=Open%20Label%20Comparative%20Study%20On%20Celecoxib%20Efficacy%20And%20Safety%20Vs%20Non-Selective%20NSAID%20In%20Acute%20Pain%20Due%20To%20Ankle%20Sprain</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2007</study_first_submitted>
  <study_first_submitted_qc>March 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <results_first_submitted>April 21, 2009</results_first_submitted>
  <results_first_submitted_qc>April 21, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2009</results_first_posted>
  <last_update_submitted>June 12, 2009</last_update_submitted>
  <last_update_submitted_qc>June 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Ankle sprain, acute pain, NSAID, celecoxib,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Sprains and Strains</mesh_term>
    <mesh_term>Ankle Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Locations used were emergency rooms at orthopedic hospitals, general hospitals or private doctor’s offices</recruitment_details>
      <pre_assignment_details>Subjects sustained ankle sprain with a pain rating of greater than or equal to 45mm on a visual analog scale on full weight bearing, no more than 48 hours prior to the first dose of study medication</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Celecoxib</title>
          <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
        </group>
        <group group_id="P2">
          <title>nsNSAIDs</title>
          <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="137"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="133"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>subject entered at another site</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not meet entrance criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Celecoxib</title>
          <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
        </group>
        <group group_id="B2">
          <title>nsNSAIDs</title>
          <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="278"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" lower_limit="18" upper_limit="66"/>
                    <measurement group_id="B2" value="30.4" lower_limit="18" upper_limit="74"/>
                    <measurement group_id="B3" value="30.5" lower_limit="18" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="167.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline at Day 3 in Pain Visual Analog Scale (VAS) - Per Protocol Population</title>
        <description>Assessment of ankle pain by VAS: 100 mm horizontal line with left end being “No Pain” &amp; right end being “Worst Possible Pain”. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at day 3 minus mean score at baseline</description>
        <time_frame>Baseline and day 3</time_frame>
        <population>Per protocol (PP) population included subjects who were randomized, received full loading dose of study medication on day 1 and took no prohibited medications up to and including day 3, had valid baseline and day 3 VAS scores and had no major protocol violations before or during the study (i.e. a subset of treated subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at Day 3 in Pain Visual Analog Scale (VAS) - Per Protocol Population</title>
          <description>Assessment of ankle pain by VAS: 100 mm horizontal line with left end being “No Pain” &amp; right end being “Worst Possible Pain”. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at day 3 minus mean score at baseline</description>
          <population>Per protocol (PP) population included subjects who were randomized, received full loading dose of study medication on day 1 and took no prohibited medications up to and including day 3, had valid baseline and day 3 VAS scores and had no major protocol violations before or during the study (i.e. a subset of treated subjects).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.88" spread="19.75"/>
                    <measurement group_id="O2" value="-40.76" spread="18.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Least squares mean</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>To conclude non inferiority, the lower bound of the 2-sided 95% confidence interval of the difference in change scores between the 2 treatment groups (nsNSAIDs - celecoxib) must be greater than –10 mm.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>7.55</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pain Visual Analog Scale (VAS) - Modified Intent to Treat Population</title>
        <description>Assessment of ankle pain by VAS: 100 mm horizontal line, left end being “No Pain” &amp; right end being “Worst Possible Pain”. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at observation minus mean score at baseline</description>
        <time_frame>Baseline and days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment (i.e. a subset of treated subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pain Visual Analog Scale (VAS) - Modified Intent to Treat Population</title>
          <description>Assessment of ankle pain by VAS: 100 mm horizontal line, left end being “No Pain” &amp; right end being “Worst Possible Pain”. Participants drew vertical line on horizontal scale to best reflect current pain on full weight bearing of injured ankle. Distance from left end of line to mark. Change: mean score at observation minus mean score at baseline</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment (i.e. a subset of treated subjects).</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.25" spread="18.99"/>
                    <measurement group_id="O2" value="-25.98" spread="18.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.87" spread="19.51"/>
                    <measurement group_id="O2" value="-40.75" spread="18.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.17" spread="18.43"/>
                    <measurement group_id="O2" value="-57.89" spread="18.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.02</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>7.08</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.04</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>7.48</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>6.42</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Responding (Improving) - MITT Population</title>
        <description>The number of subjects showing a response: a decrease of at least 20 mm (that is improvement) on the pain visual analog scale (VAS) scale</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment (i.e. a subset of treated subjects).</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Responding (Improving) - MITT Population</title>
          <description>The number of subjects showing a response: a decrease of at least 20 mm (that is improvement) on the pain visual analog scale (VAS) scale</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment (i.e. a subset of treated subjects).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 - response (N=134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - no response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - response (N=135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - no response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - response (N=133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - no response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1591</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Terms for treatment and the baseline pain VAS score</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3995</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Terms for treatment and the baseline pain VAS score</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6805</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Terms for treatment and the baseline pain VAS score</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject's Global Assessment of Ankle Injury</title>
        <description>Subject response to question: “Considering all the ways your ankle injury affects you, how are you doing today?” Scale: 5 point from 1 = very good (no symptoms and no limitation of normal activities) to 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities).</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject's Global Assessment of Ankle Injury</title>
          <description>Subject response to question: “Considering all the ways your ankle injury affects you, how are you doing today?” Scale: 5 point from 1 = very good (no symptoms and no limitation of normal activities) to 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities).</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 - Very good (no symptoms) (N=135, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - Good (mild symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - Fair (moderate symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - Poor (severe symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2- Very poor (very severe symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Very good (no symptoms) (N=135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Good (mild symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Fair (moderate symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Poor (severe symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Very poor (very severe symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Very good (no symptoms) (N=133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Good (mild symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Fair (moderate symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Poor (severe symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Very poor (very severe symptoms)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2411</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1163</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0440</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment of Ankle Injury</title>
        <description>Investigator evaluation of overall severity of ankle injury. Scale: 5 point from 1 = Very mild (very mild signs and symptoms of ankle sprain) to 5 =Very severe (very severe signs and symptoms of ankle sprain)</description>
        <time_frame>Days 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment of Ankle Injury</title>
          <description>Investigator evaluation of overall severity of ankle injury. Scale: 5 point from 1 = Very mild (very mild signs and symptoms of ankle sprain) to 5 =Very severe (very severe signs and symptoms of ankle sprain)</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 3 - very mild (N=134, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - very severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - very mild (N=132, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - very severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7223</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country
Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0541</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country
Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief - MITT Population</title>
        <description>Subject's response to the statement &quot;My relief from starting pain is&quot;. Scale from 0 = None to 4 = Complete.</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief - MITT Population</title>
          <description>Subject's response to the statement &quot;My relief from starting pain is&quot;. Scale from 0 = None to 4 = Complete.</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 - None (N=135, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - Some</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 -Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - None (N=135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - Some</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 -Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - None (N=133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - A little</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - Some</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - A lot</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 -Complete</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2900</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country
Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0157</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country
Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1206</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country
Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Normal Function / Activity</title>
        <description>Subject response to question: “How does your ankle injury affect your walking and normal activity?” Scale from 1 = Normal walking/activity and no pain to 5 = Severely restricted walking due to pain and can’t resume normal activities (normal activities defined as all activity that a subject did on a routine basis, including work and recreation)</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Assessment of Normal Function / Activity</title>
          <description>Subject response to question: “How does your ankle injury affect your walking and normal activity?” Scale from 1 = Normal walking/activity and no pain to 5 = Severely restricted walking due to pain and can’t resume normal activities (normal activities defined as all activity that a subject did on a routine basis, including work and recreation)</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 - normal no pain (N =135, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - normal with pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - mildly restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - moderately restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2 - severely restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - normal no pain (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - normal with pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - mildly restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - moderately restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 - severely restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - normal no pain (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - normal with pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - mildly restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - moderately restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 - severely restricted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0846</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3041</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1216</p_value>
            <p_value_desc>Threshold for statistical significance: p value is less than or equal to 0.05</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Controlled for country Test of row mean score differences based on modified ridits (standardizing the mid-rank)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 1</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q1: Subject response to 'describe your pain at its worst in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
        <time_frame>Days 1, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 1</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q1: Subject response to 'describe your pain at its worst in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" spread="2.04"/>
                    <measurement group_id="O2" value="5.90" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.81" spread="1.84"/>
                    <measurement group_id="O2" value="4.44" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.08" spread="1.93"/>
                    <measurement group_id="O2" value="2.38" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.395</p_value>
            <p_value_desc>Overall p-value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.14</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.61</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.18</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.122</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.77</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 2</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q2: Subject response to 'describe your pain at its least in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 2</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q2: Subject response to 'describe your pain at its least in the last 24 hours'. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 133, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="1.83"/>
                    <measurement group_id="O2" value="3.36" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="1.68"/>
                    <measurement group_id="O2" value="2.40" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="1.26"/>
                    <measurement group_id="O2" value="1.16" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.604</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.062</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 3</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q3: Subject response to 'describe your pain on the average'. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 3</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q3: Subject response to 'describe your pain on the average'. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" spread="1.79"/>
                    <measurement group_id="O2" value="4.41" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="1.70"/>
                    <measurement group_id="O2" value="3.26" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.56"/>
                    <measurement group_id="O2" value="1.74" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.705</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.064</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.074</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 4</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q4: Subject response to 'how much pain you have right now'. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Question 4</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q4: Subject response to 'how much pain you have right now'. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="2.05"/>
                    <measurement group_id="O2" value="4.23" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N =135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.58" spread="1.81"/>
                    <measurement group_id="O2" value="2.92" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="1.56"/>
                    <measurement group_id="O2" value="1.43" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.11</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.74</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.117</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Index</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Pain severity index is the average of the pain severity questions 1 to 4. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) - Pain Severity Index</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Pain severity index is the average of the pain severity questions 1 to 4. Scale: 0 = no pain to 10 = pain as bad as you can imagine</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.24" spread="1.66"/>
                    <measurement group_id="O2" value="4.48" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread="1.61"/>
                    <measurement group_id="O2" value="3.26" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="1.47"/>
                    <measurement group_id="O2" value="1.68" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.21</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.070</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5A</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5A: Subject response to ‘how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5A</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5A: Subject response to ‘how, during the past 24 hours, pain has interfered with your general activity. Scale: 0 = does not interfere to 10 = completely interferes</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" spread="2.52"/>
                    <measurement group_id="O2" value="5.37" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.65" spread="2.64"/>
                    <measurement group_id="O2" value="4.07" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="2.13"/>
                    <measurement group_id="O2" value="1.90" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.954</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.172</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.541</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5B</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5B: Subject response to ‘how, during the past 24 hours, pain has interfered with your mood’. Scale: 0 = does not interfere to 10 = completely interferes</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5B</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5B: Subject response to ‘how, during the past 24 hours, pain has interfered with your mood’. Scale: 0 = does not interfere to 10 = completely interferes</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.72" spread="2.95"/>
                    <measurement group_id="O2" value="3.64" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.43" spread="2.41"/>
                    <measurement group_id="O2" value="2.38" spread="2.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="2.06"/>
                    <measurement group_id="O2" value="1.26" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.924</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.898</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.29</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.655</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5C</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5C: Subject response to ‘how, during the past 24 hours, pain has interfered with your walking ability’. Scale: 0 = does not interfere to 10 = completely interferes</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5C</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5C: Subject response to ‘how, during the past 24 hours, pain has interfered with your walking ability’. Scale: 0 = does not interfere to 10 = completely interferes</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="2.76"/>
                    <measurement group_id="O2" value="5.11" spread="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="2.62"/>
                    <measurement group_id="O2" value="3.69" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" spread="2.19"/>
                    <measurement group_id="O2" value="1.62" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.929</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.712</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.993</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5D</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5D: Subject response to ‘how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)’. Scale: 0 = does not interfere to 10 = completely interferes</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5D</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5D: Subject response to ‘how, during the past 24 hours, pain has interfered with your normal work (work outside the home and housework)’. Scale: 0 = does not interfere to 10 = completely interferes</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="2.95"/>
                    <measurement group_id="O2" value="5.39" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.04" spread="2.92"/>
                    <measurement group_id="O2" value="4.04" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" spread="2.42"/>
                    <measurement group_id="O2" value="1.87" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.779</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.11</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.75</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.972</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.844</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5E</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5E: Subject response to ‘how, during the past 24 hours, pain has interfered with your relations with other people’. Scale: 0 = does not interfere to 10 = completely interferes</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5E</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5E: Subject response to ‘how, during the past 24 hours, pain has interfered with your relations with other people’. Scale: 0 = does not interfere to 10 = completely interferes</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="2.78"/>
                    <measurement group_id="O2" value="2.67" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="2.26"/>
                    <measurement group_id="O2" value="1.69" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="1.70"/>
                    <measurement group_id="O2" value="0.78" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.944</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.654</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.62</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.952</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.39</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5F</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5F: Subject response to ‘how, during the past 24 hours, pain has interfered with your sleep’. Scale: 0 = does not interfere to 10 = completely interferes</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5F</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5F: Subject response to ‘how, during the past 24 hours, pain has interfered with your sleep’. Scale: 0 = does not interfere to 10 = completely interferes</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="2.88"/>
                    <measurement group_id="O2" value="2.87" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="2.40"/>
                    <measurement group_id="O2" value="1.86" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="1.77"/>
                    <measurement group_id="O2" value="0.82" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.842</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.31</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.828</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.27</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.49</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.542</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.21</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.53</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5G</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5G: Subject response to ‘how, during the past 24 hours, pain has interfered with your enjoyment of life’. Scale: 0 = does not interfere to 10 = completely interferes</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Question 5G</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
Q5G: Subject response to ‘how, during the past 24 hours, pain has interfered with your enjoyment of life’. Scale: 0 = does not interfere to 10 = completely interferes</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" spread="3.17"/>
                    <measurement group_id="O2" value="2.99" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="2.69"/>
                    <measurement group_id="O2" value="2.06" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" spread="1.98"/>
                    <measurement group_id="O2" value="1.10" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.404</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.92</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.816</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.28</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.53</ci_lower_limit>
            <ci_upper_limit>0.58</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.837</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.23</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Index</title>
        <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
The pain interference index is the average of pain interference questions 5A to 5G. Scale: 0 = does not interfere to 10 = completely interferes</description>
        <time_frame>Days 2, 3 and 7</time_frame>
        <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Celecoxib</title>
            <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
          </group>
          <group group_id="O2">
            <title>nsNSAIDs</title>
            <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Brief Pain Inventory Short Form (m-BPI-sf) – Pain Interference Index</title>
          <description>m-BPI-sf questionnaire assessed pain severity and pain interference with functional activities during the 24 hour follow-up period.
The pain interference index is the average of pain interference questions 5A to 5G. Scale: 0 = does not interfere to 10 = completely interferes</description>
          <population>Modified intent to treat (MITT) population included subjects who were randomized, received at least one dose of study medication and had at least one follow up pain VAS score assessment</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 2 (N = 134, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" spread="2.34"/>
                    <measurement group_id="O2" value="4.01" spread="2.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3 (N = 135, 131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="2.15"/>
                    <measurement group_id="O2" value="2.83" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7 (N = 133, 125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="1.81"/>
                    <measurement group_id="O2" value="1.33" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 2 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.887</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.25</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.54</ci_lower_limit>
            <ci_upper_limit>0.45</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 3 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.889</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.24</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 7 Least squares mean</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.738</p_value>
            <p_value_desc>Overall p value</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Terms for treatment and country</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
            <estimate_desc>Direction: nsNSAIDs minus celecoxib</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Celecoxib</title>
          <description>All participants randomized to celecoxib were treated with 2 capsules of celecoxib 200 mg as a loading dose, thereafter, participants took 1 capsule of celecoxib 200 mg twice daily (morning and evening), for up to 7 days. Approximately a 12 hour interval was maintained between doses.</description>
        </group>
        <group group_id="E2">
          <title>nsNSAIDs</title>
          <description>All participants randomized to non-selective non-steroidal anti inflammatory drugs (nsNSAIDs) took the first dose and all subsequent doses according to the standard treatment practice for treatment of pain due to ankle sprain, for up to 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13"/>
                <counts group_id="E2" subjects_affected="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

